Literature DB >> 33053159

Metabolomics of Lean/Overweight Insulin-Resistant Females Reveals Alterations in Steroids and Fatty Acids.

Ilhame Diboun1, Layla Al-Mansoori2, Hend Al-Jaber2, Omar Albagha1, Mohamed A Elrayess2.   

Abstract

BACKGROUND: The global diabetes epidemic is largely attributed to obesity-triggered metabolic syndrome. However, the impact of insulin resistance (IR) prior to obesity on the high prevalence of diabetes and the molecular mediators remain largely unknown. This study aims to compare the metabolic profiling of apparently healthy lean/overweight participants with IR and insulin sensitivity (IS), and identify the metabolic pathways underlying IR.
METHODS: In this cross-sectional study, clinical and metabolic data for 200 seemingly healthy young female participants (100 IR and 100 IS) was collected from Qatar Biobank. Orthogonal partial least square analysis was performed to assess the extent of separation between individuals from the 2 groups based on measured metabolites. Classical linear models were used to identify the metabolic signature of IR, followed by elastic-net-regularized generalized linear model (GLMNET) and receiver operating characteristic (ROC) analysis to determine top metabolites associated with IR.
RESULTS: Compared to lean/overweight participants with IS, those with IR showed increased androgenic steroids, including androsterone glucuronide, in addition to various microbiota byproducts, such as the phenylalanine derivative carboxyethylphenylalanine. On the other hand, participants with IS had elevated levels of long-chain fatty acids. A ROC analysis suggested better discriminatory performance using 20 metabolites selected by GLMNET in comparison to the classical clinical traits (area under curve: 0.93 vs 0.73, respectively).
CONCLUSION: Our data confirm the multifactorial mechanism of IR with a diverse spectrum of emerging potential biomarkers, including steroids, long-chain fatty acids, and microbiota metabolites. Further studies are warranted to validate these markers for diagnostic and therapeutic applications.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  biomarkers; insulin resistance; insulin sensitivity; lean/overweight; metabolomics

Year:  2021        PMID: 33053159     DOI: 10.1210/clinem/dgaa732

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Metabolic Signature of Leukocyte Telomere Length in Elite Male Soccer Players.

Authors:  Shamma Al-Muraikhy; Maha Sellami; Alexander S Domling; Najeha Rizwana; Abdelali Agouni; Fatima Al-Khelaifi; Francesco Donati; Francesco Botre; Ilhame Diboun; Mohamed A Elrayess
Journal:  Front Mol Biosci       Date:  2021-12-16

2.  Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy.

Authors:  Nicola Stefano Fracchiolla; Ujjwal Neogi; Elisa Saccon; Alessandra Bandera; Mariarita Sciumè; Flora Mikaeloff; Abid A Lashari; Stefano Aliberti; Michael C Sachs; Filippo Billi; Francesco Blasi; Erin E Gabriel; Giorgio Costantino; Pasquale De Roberto; Shuba Krishnan; Andrea Gori; Flora Peyvandi; Luigia Scudeller; Ciro Canetta; Christian L Lorson; Luca Valenti; Kamal Singh; Luca Baldini
Journal:  Microbiol Spectr       Date:  2021-09-01

3.  Comparing the Metabolic Profiles Associated with Fitness Status between Insulin-Sensitive and Insulin-Resistant Non-Obese Individuals.

Authors:  Shamma AlMuraikhy; Najeha Anwardeen; Aisha Naeem; Maha Sellami; Alexander Domling; Abdelali Agouni; Mohamed A Elrayess
Journal:  Int J Environ Res Public Health       Date:  2022-09-26       Impact factor: 4.614

4.  Comparing Levels of Metabolic Predictors of Coronary Heart Disease between Healthy Lean and Overweight Females.

Authors:  Rasha Abu-El-Ruz; Manar E Abdel-Rahman; Stephen L Atkin; Mohamed A Elrayess
Journal:  Metabolites       Date:  2021-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.